#1
|
|||
|
|||
ÈÔÐ-I
äî 3 ëåò: 16-215 ng/ml
3-6 ëåò: 58-159 ng/ml 6-9 ëåò: 64-406 ng/ml 9-12 ëåò: 38-318 ng/ml 12-15 ëåò: 39-537 ng/ml 19-24 ëåò 49-550 ng/ml 25-29 ëåò: 62-280 ng/ml 30-39 ëåò: 40-280 ng/ml 40-49 ëåò: 40-256 ng/ml 50-59 ëåò: 66-310 ng/ml ïîñëå 60 ëåò: 118-314 ng/ml ìîæåò ëè áûòü ïîäîáíàÿ òàáëèöà âàðèàíòîì íîðìû äëÿ ÈÔÐ-I, äåëî â òîì, ÷òî ìåíÿ ñìóùàåò îòñóòñòâèå òåíäåíöèè óìåíüøåíèÿ âåðõíåé ãðàíèöû (40-49 - 256, 50-59 - 310). Ëîãèêà âåäü êàêîâà - ñ âîçðàñòîì ïðîäóêöèÿ ÃÐ óìåíüøàåòñÿ, ñëåäîâàòåëüíî äîëæíà óìåíüøàòñÿ è ïðîäóêöèÿ ÈÔÐ-I. À â ñëó÷àå ñ ýòîé òàáëèöåé ïîëó÷àåòñÿ, ÷òî âåðõíÿÿ ãðàíèöà íîðìû ó òåõ êîìó çà 50 áîëüøå, ÷åì ó òåõ êîìó 30-40. |
#2
|
||||
|
||||
À îòêóäà Âû âçÿëè ýòè íîðìû?
|
#3
|
|||
|
|||
Ïðîñèë ëàáîðàòîðèþ [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] âûñëàòü íîðìû
|
#4
|
||||
|
||||
ß íå çíàþ òî÷íîãî îòâåòà íà Âàø âîïðîñ (íàäî ïî÷èòàòü ïî ÈÔÐ), íî ïðåäïîëàãàþ ñëåäóþùåå.
Íîðìû óñòàíàâëèâàþòñÿ ïî ñðåäíèì çíà÷åíèÿì â âûáîðêå çäîðîâûõ ëèö. Ëèöà ñòàðøå 50 ëåò ÷àùå èìåþò îæèðåíèå, ÷åì ôåðòèëüíàÿ ÷àñòü ïîïóëÿöèè. À ÈÔÐ-1 âûðàáàòûâàåòñÿ, â ÷àñòíîñòè, àäèïîöèòàìè. Âîò òàêàÿ ãèïîòåçà î ñìóùàþùèõ Âàñ íîðìàõ. |
#5
|
|||
|
|||
Öèòàòà:
âåäóùèå ýíäîêðèíîëîãè. Ðàçâå ýòî íå òàê? |
#6
|
||||
|
||||
Åñëè ó Âàñ åñòü ññûëêè, ïîæàëóéñòà äàéòå. ß ïîñìîòðþ ïóáëèêàöèè. Ïîêà áåðó òàéì-àóò.
|
#7
|
|||
|
|||
Öèòàòà:
"...The effects of GH and IGF-I on muscle and bone metabolism seem to be synergistic. Both hormones increase muscle mass, activate bone remodeling units, and improve bone density. Although IGF-I in serum is predominantly of hepatic origin (85%)....." "...The term “somatopause” has been used by some investigators to suggest that normal aging is associated with a gradual decline in secretion of GH accompanied by a decrease in bone mass and lean body mass as well as an increase in adipose mass..." [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] "...In aging men, GH secretion declines by 50% every 7 years after age 18-25 years...." [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] growth-hormone-replacement-in-older-men.htm "...GH in circulation acts on many tissues and organs. One of the main tasks of GH is to increase the production of a substance by the liver, called Insulin-like Growth Factor-I (IGF-I). Circulating IGF-I levels undergo important age-related variations increasing at puberty and decreasing, thereafter, to low levels in the elderly. Low IGF-I levels in the elderly mainly reflect impaired GH secretion but the decline in gonadal sex steroid levels, and malnutrition may also play a role in the age-related decrease in IGF-I activity. This, in turn, partially accounts for age-related changes in bones, muscles, cardiovascular system, central nervous system and the immune system...." [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#8
|
||||
|
||||
Íà ñàìîì äåëå, ñ ÈÔÐ-1 íå âñ¸ ïðîñòî. Îí ìíîãî îò ÷åãî çàâèñèò, äàæå îò ðåæèìà ïèòàíèÿ...
"Sequential, randomized trial of a low-fat, high-fiber diet and soy supplementation: effects on circulating IGF-I and its binding proteins in premenopausal women. Gann PH, Kazer R, Chatterton R, Gapstur S, Thedford K, Helenowski I, Giovanazzi S, Van Horn L. Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Despite evidence supporting the involvement of the IGF system in the development of breast and other cancers, the major determinants of interindividual variability in circulatory IGF-I levels are not well understood. Previous research has pointed to important genetic influences as well as dietary effects through marked calorie or protein restriction. We conducted a randomized trial to determine the effects of 2 dietary patterns on serum IGF-1, IGFBP1 and IGFBP3 in free-living premenopausal women: phase 1, an isocaloric low-fat, high-fiber (LFHF) vs. usual diet, and phase 2, a soy supplement either with or without isoflavones (soy+IF vs. soy-IF). Participants completed 12 menstrual cycles on phase 1 and then were randomly assigned to a soy supplement for 3 cycles while maintaining the phase 1 diet. Before and after each phase, 154 women provided serum. We found no difference in the change in IGF-I, BP1 or BP3 in the LFHF group compared to the usual diet group. In phase 2, there were no differences in any IGF protein between the soy+IF and the soy-IF groups or any evidence of interaction between isoflavone exposure and the background diet. However, there was a small but statistically significant decrease (2.3%) in BP3 and an increase in the IGF-I:BP3 molar ratio among all 153 subjects following either soy supplement. These changes were correlated with changes in intake of calcium, total vegetable protein and soy. The results are compatible with previous data suggesting that increases in dietary calcium, protein and soy, in particular, could increase circulating levels of bioavailable IGF-I. Copyright 2005 Wiley-Liss, Inc." Âîò çäåñü ìíîãî ññûëîê ïî èíòåðåñóþùåé Âàñ òåìå. Ïîñìîòðèòå, ïîæàëóéñòà: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#9
|
||||
|
||||
Ìàêñâåëë ! Âåäóùèå ýíäîêðèíîëîãè, êîãäà ðàçîéäóòñÿ, è íå òî íàãîâîðÿò- ïðî ñâÿçûâàþùèå ÈÏÐÔ áåëêè íå õîòèòå ?
Ïðî ðîëü äðóãèõ ãîðìîíîâ ? Äàâàéòå åùå ðàç- ãîðìîíû ïðèäóìàëè íå äëÿ òîãî, ÷òîáû óìíûå ìàëü÷èêè èõ ñìîòðåëè ó ñåáÿ, à ïîòîì äîñòàâàëè îêðóæàþùèõ îòêëîíåíèÿìè îò íðàâÿùèõñÿ èì ñòàíäðàòîâ. Îáñëåäîâàíèå ËÞÁÎÃÎ ïàöèåíòà ñòðîèòñÿ ïî ñëåäóþùåìó ïëàíó - æàëîáû - îñìîòð- äèàãíîñòè÷åñêàÿ ãèïîòåçà-îáñëåäîâàíèå, íàïðàâëåííîå íà åå ïîäòâåðæäåíèå, îáñëåäîâàíèå, íàïðàâëåííîå íà èñêëþ÷åíèå ïîòåíöèàëüíî âîçìîæíûõ ñõîäíûõ, íî ìåíåå âåðîÿòíûõ ñèòóàöèé. Ó Âàñ ïðîáëåìû, Âû íàì î íèõ ïèñàëè . Âðà÷- àíàëèçû, êîòîðûå îí íàçíà÷èò- îáñóæäåíèå ïðîáëåì. È ïîéäèòå ïîãóëÿéòå.
__________________
Ã.À. Ìåëüíè÷åíêî |
#10
|
|||
|
|||
Óâàæàåìàÿ ãîñïîæà Ìåëüíè÷åíêî,
ß âîîáùå-òî íå ìåäèê. Ñïîðèòü î ãîðìîíàõ ìíå íå äîñòàâëÿåò îñîáîãî óäîâîëüñòâèÿ. ß ñîâñåì íå ðàä, ÷òî òîãäà ñâÿçàëñÿ òîãäà ñ ñîìàòðîïèíîì èíñóëèíîì è ìåòàíäðîñòåíîëîíîì. Õîòÿ áû àíãèîïàòèÿ ñåò÷àòêè(ïîòàâëåííàÿ îêóëèñòîì) ïîñëå ýòîãî íàâîäèò íà ìûñëü î ñåðüåçíûõ ïîñëåäñòâèÿõ. À ïî÷åìó ÿ ñïîðþ, òàê ýòî ïîòîìó, ÷òî ÿ íå äîâåðÿþ âñåì âðà÷àì, ïîòîìó ÷òî ïî äàííûì ÌÐÒ òîëüêî îäèí èç 5 íåâðîïàòîëîãîâ ïîñòàâèëâ çàêëþ÷åíèè ïðèçíàêè ëåãêîé ãèäðîöåôàëèè. Ëåãêàÿ/íå ëåãêàÿ. À âîò èñòîðèÿ ñ ýíäîêðèíîëîãàìè: îäíà ïîñòàâèëà ìíå ãèïîòàëàìè÷åñêèé ñèíäðîì è ïîñëå ÓÇÈ ùèòîâèäíîé æåëåçû äèôôóçíûé çîá I ýóòèðåîç. Äðóãàÿ ïðî ãèïîòàëàìè÷åñêèé ñèíäðîì íè÷åãî íå ñêàçàëà è ñêàçàëà, ÷òî âñå íîðìàëüíî. Ïîýòîìó ÿ ïûòàþñü ñàì ðàçîáðàòüñÿ â ñóòè äåëà. Îïûòà è Âàøèõ çíàíèé êîíå÷íî ÿ íå èìåþ.... |
#11
|
||||
|
||||
Öèòàòà:
Ïðèíîøó ñâîè èçâèíåíèÿ, ÷òî âñòóïèëà ñ Âàìè â ïðîôåññèîíàëüíóþ äèñêóññèþ. Íå ïîèíòåðåñîâàâøèñü Âàøèì ïðîôèëåì ó÷àñòíèêà ôîðóìà, ðåøèëà, ÷òî áåñåäóþ ñî ñòóäåíòîì - ìåäèêîì, ïûòàþùèìñÿ ðàçîáðàòüñÿ â îïðåäåëåííûõ âîïðîñàõ. Íèêàê íå îæèäàëà, ÷òî ïàöèåíò, îò÷àÿâøèñü ïîëó÷èòü àäåêâàòíóþ ïîìîùü, ïîëåçåò â òàêèå "çàóìíûå äåáðè". Ïîâåðüòå, ñàìè Âû íè â ÷¸ì íå ðàçáåðåòåñü. Çàïóòàåòåñü îêîí÷àòåëüíî. Âàì íåîõîäèìà êîíñóëüòàöèÿ âðà÷à. Òîëüêî âðà÷ ñìîæåò ðàçîáðàòüñÿ â Âàøèõ ïðîáëåìàõ è íàçíà÷èòü àäåêâàòíîå ëå÷åíèå. Ýòó òåìó ÿ çàêðûâàþ. |